While 105 (89.0%) patients were candidates for conversion surgery after first-line cytotoxic chemotherapy with or without ICIs and/or HER2 inhibitors, the other 13 (11.0%) patients achieved adequate tumor regression in further lines of therapy, and 9 of them were assigned by specific biomarkers—2 with HER2+, 1 with MSI-H, 1 with dMMR, 1 with EBV+/PD-L1+, and 4 with MET amplifications. This evidence concerns the gene ERBB2 and neoplasm.